Abivax (ABVX) Shares Outstanding (Weighted Average) (2021 - 2026)

Abivax's Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $928.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 1292.59% year-over-year to $928.4 million; the TTM figure through Mar 2026 stood at $928.4 million (up 1292.59% YoY), while the FY2025 annual figure was $913.8 million, up 1256.33% from the prior year.
• Shares Outstanding (Weighted Average) was $928.4 million for Q1 2026 at Abivax, up from $913.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $928.4 million in Q1 2026 to a low of $738.73 in Q1 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $338.2 million across 5 years, with a median of $67.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) tumbled 98.71% in 2022, then surged 51344049.83% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $227515.2 in 2022, then soared by 20266.31% to $46.3 million in 2023, then jumped by 45.4% to $67.4 million in 2024, then jumped by 1256.33% to $913.8 million in 2025, then grew by 1.6% to $928.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $928.4 million (Q1 2026), $913.8 million (Q4 2025), and $909.5 million (Q3 2025), per Business Quant data.